Biogenerics Get A Low Score From CBO, But Is BIO Actually The Loser?
Executive Summary
The reaction of stakeholders to the Congressional Budget Office's score of potential savings from follow-on biologics illustrates the challenges for the various players as debate on legislation continues
You may also be interested in...
Follow-On Biologics' Bumpy Pathway: Was The CBO Savings Score Too High?
The promise of health care savings from an abundance of biosimilar drugs brought to market under recently passed reforms may go unfulfilled if intellectual property provisions of the law aren't addressed, members of a panel at the BIO annual meeting in Chicago said May 5
Follow-On Biologics' Bumpy Pathway: Was The CBO Savings Score Too High?
The promise of health care savings from an abundance of biosimilar drugs brought to market under recently passed reforms may go unfulfilled if intellectual property provisions of the law aren't addressed, members of a panel at the BIO annual meeting in Chicago said May 5
Follow-on Biologics Savings Lower In Administration Budget Proposal
The Obama administration has cut by about one-third its estimate of the fiscal benefit expected to accrue to the treasury from an approval pathway for follow-on biologics